SWOG 1318: A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone Vincristine Methotrexate 6-Mercaptopurine) for Patients 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517) Prednisone and Blinatumomab for Patients 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+)

SWOG 1318: A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone Vincristine Methotrexate 6-Mercaptopurine) for Patients 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517) Prednisone and Blinatumomab for Patients 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+)
99 years or below
All
Phase 2
1 Location

Brief description of study

Request for review: CIRB Authorization Agreement, see attached.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: TBD, tbd, tbd
  • Age: 99 years or below
  • Gender: All
Updated on 27 Aug 2018. Study ID: 823406

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.